KalVista Pharmaceuticals (NASDAQ:KALV) CFO Sells $27,512.19 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CFO Brian Piekos sold 1,767 shares of the business’s stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $27,512.19. Following the completion of the transaction, the chief financial officer directly owned 13,762 shares in the company, valued at $214,274.34. This trade represents a 11.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

KalVista Pharmaceuticals Price Performance

KALV traded up $0.21 during trading on Tuesday, hitting $15.77. 751,567 shares of the company traded hands, compared to its average volume of 635,299. The company has a current ratio of 7.22, a quick ratio of 7.21 and a debt-to-equity ratio of 8.18. The company has a market cap of $797.17 million, a PE ratio of -3.99 and a beta of -0.19. The stock’s 50-day simple moving average is $15.47 and its two-hundred day simple moving average is $13.94. KalVista Pharmaceuticals, Inc. has a 1 year low of $9.23 and a 1 year high of $19.00.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the company. Wall Street Zen raised KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, December 6th. Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Citizens Jmp decreased their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday, November 11th. TD Cowen reiterated a “buy” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 3rd. Finally, HC Wainwright boosted their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a “buy” rating in a research report on Friday, January 9th. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $29.40.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. The Manufacturers Life Insurance Company raised its position in KalVista Pharmaceuticals by 5.9% during the second quarter. The Manufacturers Life Insurance Company now owns 14,626 shares of the specialty pharmaceutical company’s stock valued at $165,000 after purchasing an additional 818 shares during the period. BNP Paribas Financial Markets increased its position in shares of KalVista Pharmaceuticals by 47.0% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the last quarter. Rhumbline Advisers increased its position in shares of KalVista Pharmaceuticals by 2.8% during the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock valued at $615,000 after purchasing an additional 1,458 shares during the last quarter. Police & Firemen s Retirement System of New Jersey raised its holdings in KalVista Pharmaceuticals by 26.8% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company’s stock valued at $110,000 after buying an additional 2,061 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in KalVista Pharmaceuticals by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 324,369 shares of the specialty pharmaceutical company’s stock worth $5,239,000 after buying an additional 2,402 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.